1. Home
  2. CLRB vs MCVT Comparison

CLRB vs MCVT Comparison

Compare CLRB & MCVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLRB
  • MCVT
  • Stock Information
  • Founded
  • CLRB 2002
  • MCVT 2007
  • Country
  • CLRB United States
  • MCVT United States
  • Employees
  • CLRB N/A
  • MCVT N/A
  • Industry
  • CLRB Biotechnology: Pharmaceutical Preparations
  • MCVT Finance Companies
  • Sector
  • CLRB Health Care
  • MCVT Finance
  • Exchange
  • CLRB Nasdaq
  • MCVT Nasdaq
  • Market Cap
  • CLRB 10.7M
  • MCVT 11.6M
  • IPO Year
  • CLRB N/A
  • MCVT N/A
  • Fundamental
  • Price
  • CLRB $0.25
  • MCVT $1.93
  • Analyst Decision
  • CLRB Buy
  • MCVT
  • Analyst Count
  • CLRB 2
  • MCVT 0
  • Target Price
  • CLRB $28.00
  • MCVT N/A
  • AVG Volume (30 Days)
  • CLRB 3.8M
  • MCVT 6.2K
  • Earning Date
  • CLRB 11-18-2024
  • MCVT 11-12-2024
  • Dividend Yield
  • CLRB N/A
  • MCVT N/A
  • EPS Growth
  • CLRB N/A
  • MCVT N/A
  • EPS
  • CLRB N/A
  • MCVT 0.05
  • Revenue
  • CLRB N/A
  • MCVT $3,234,265.00
  • Revenue This Year
  • CLRB N/A
  • MCVT N/A
  • Revenue Next Year
  • CLRB N/A
  • MCVT N/A
  • P/E Ratio
  • CLRB N/A
  • MCVT $39.90
  • Revenue Growth
  • CLRB N/A
  • MCVT N/A
  • 52 Week Low
  • CLRB $0.23
  • MCVT $1.75
  • 52 Week High
  • CLRB $4.45
  • MCVT $3.88
  • Technical
  • Relative Strength Index (RSI)
  • CLRB 6.45
  • MCVT 46.34
  • Support Level
  • CLRB $0.23
  • MCVT $1.91
  • Resistance Level
  • CLRB $0.28
  • MCVT $2.00
  • Average True Range (ATR)
  • CLRB 0.07
  • MCVT 0.06
  • MACD
  • CLRB -0.10
  • MCVT 0.01
  • Stochastic Oscillator
  • CLRB 2.70
  • MCVT 23.81

About CLRB Cellectar Biosciences Inc.

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

About MCVT Mill City Ventures III Ltd.

Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions primarily to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that they provide are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.

Share on Social Networks: